MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
4.590
+0.100 (2.23%)
At close: Aug 29, 2025, 4:00 PM
4.580
-0.010 (-0.22%)
After-hours: Aug 29, 2025, 6:28 PM EDT

Company Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States.

It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension.

The company’s product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus.

It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis.

Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder.

MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MannKind Corporation
MannKind logo
CountryUnited States
Founded1991
IPO DateJul 28, 2004
IndustryBiotechnology
SectorHealthcare
Employees407
CEOMichael Castagna

Contact Details

Address:
1 Casper Street
Danbury, Connecticut 06810
United States
Phone818 661 5000
Websitemannkindcorp.com

Stock Details

Ticker SymbolMNKD
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000899460
CUSIP Number56400P706
ISIN NumberUS56400P7069
Employer ID13-3607736
SIC Code2834

Key Executives

NamePosition
Dr. Michael E. Castagna Pharm.D.Chief Executive Officer and Director
Christopher B. Prentiss M.B.A.Chief Financial Officer
Dr. David B. Thomson J.D., Ph.D.Executive Vice President, General Counsel and Secretary
Sanjay Singh M.B.A.Executive Vice President of Technical Operations
Rosabel Realica Alinaya CPAVice President of Investor Relations and Treasury
Dr. Stuart A. Tross Ph.D.Executive Vice President of Human Resources
John F. BedardSenior Vice President of Worldwide Regulatory Affairs
Dr. Kevin Kaiserman M.D.Senior Vice President and Therapeutic Area Head of Endocrine Diseases
Dominic Marasco R.Ph.President of Endocrine Business Unit

Latest SEC Filings

DateTypeTitle
Aug 27, 20258-KCurrent Report
Aug 25, 2025SC TO-CFiling
Aug 25, 20258-KCurrent Report
Aug 6, 202510-QQuarterly Report
Aug 6, 20258-KCurrent Report
Jul 16, 2025144Filing
Jul 16, 2025144Filing
Jun 10, 2025144Filing
May 20, 2025144Filing
May 20, 2025144Filing